Table 1. Association of plasma serotonin concentrations with clinical outcomes.
Clinical outcomes | Remission at 4 weeks | Remission at 8 weeks | Response at 4 weeks | Response at 8 weeks | % change at 4 weeks | % change at 8 weeks |
---|---|---|---|---|---|---|
Baseline | P=0.012 | P=0.028 | P=0.007 | P=0.047 | P=0.015 | P=0.019 |
OR=1.41 | OR=1.31 | OR=1.40 | OR=1.30 | r=−0.14 | r=−0.14 | |
Change after 4 weeks | P=0.011 | P=0.041 | P=0.026 | P=0.060 | P=0.021 | P=0.024 |
OR=1.40 | OR=1.27 | OR=1.31 | OR=1.27 | r=−0.13 | r=−0.13 | |
Change after 8 weeks | P=0.069 | P=0.147 | P=0.037 | P=0.130 | P=0.041 | P=0.06 |
OR=1.27 | OR=1.19 | OR=1.29 | OR=1.21 | r=−0.12 | r=−0.11 |
Abbreviation: OR, odds ratio; SSRI, selective serotonin reuptake inhibitor. Plasma serotonin concentrations at baseline and decreases in plasma serotonin concentrations after 4 weeks of SSRI treatment were nominally associated with remission, response and percent change in QIDS-C16 score. The decrease in plasma serotonin between baseline and 8 weeks of SSRI treatment was associated only with the response at 4 weeks and percent change in QIDS-C16 at 4 weeks. OR>1 indicates improvement (associated with higher baseline and larger changes in plasma serotonin concentrations) and the negative r values indicate a decrease in QIDS-C16 scores, i.e., improvement. P-values<0.05 have been bolded.